

COMPLETE LISTING OF CLAIMS

1. **(Withdrawn)** A pharmaceutical composition for treating an inner ear disorder, the composition comprising an agent that modulates glutamate-mediated neurotransmission or sodium channel function without causing significant clinical hearing loss associated with suppression of AMPA receptor-mediated signals.
2. **(Withdrawn)** The pharmaceutical composition of claim 1, wherein the agent inhibits pre-synaptic release of glutamate.
3. **(Withdrawn)** The pharmaceutical composition of claim 1, wherein the agent inhibits glutamate-mediated neurotransmission post-synaptically.
4. **(Withdrawn)** The pharmaceutical composition of claim 1, wherein the agent is a glutamate ionotropic receptor antagonist.
5. **(Withdrawn)** The pharmaceutical composition of claim 4, wherein the glutamate ionotropic receptor antagonist is an NMDA receptor antagonist.
6. **(Withdrawn)** The pharmaceutical composition of claim 5, wherein the NMDA receptor antagonist is selected from the group consisting of: D-AP5, MK 801, 7-chlorokynurene, gacyclidine, and derivatives or analogues thereof.
7. **(Withdrawn)** A system for delivery of a drug to the round window membrane of the inner ear to treat an inner ear disorder, wherein the system comprises a sustained-release drug delivery device and a drug, and wherein the drug modulates glutamate-mediated neurotransmission without causing significant clinical hearing loss associated with suppression of AMPA receptor-mediated signals, and wherein the drug is delivered to the round window membrane over a period of at least 24 hours.

8. **(Withdrawn)** The system of claim 7 wherein the drug is an NMDA receptor antagonist.
9. **(Withdrawn)** The system of claim 8 wherein the NMDA receptor antagonist is selected from the group consisting of: D-AP5, MK 801, 7-chlorokynurename, gacyclidine, and derivatives or analogues thereof.
10. **(Withdrawn)** The system of claim 8 wherein the drug delivery device comprises a pump
11. **(Withdrawn)** The system of claim 8 wherein the drug delivery device comprises a catheter.
12. **(Withdrawn)** The system of claim 8, wherein the drug is delivered at a rate of from about 0.1 mg per hour to 200 mg per hour for a period of at least 24 hours.
13. **(Withdrawn)** The system of claim 8, wherein the drug is delivered to the round window membrane of the inner ear for a period of at least about 3 days.
14. **(Currently Amended)** A method for treating an inner ear disorder in a subject, the disorder being caused by aberrant glutamate-mediated neurotransmission, the method comprising:
administering directly to the inner ear to a round window membrane of a subject suffering from an inner ear disorder, a formulation comprising an agent that modulates glutamate-mediated neurotransmission or sodium channel function selected from the group consisting of: D-AP5, MK 801, 7-chlorokynurename and gacyclidine, thereby treating the inner ear disorder in the subject,
wherein said administration results in passage of the agent through the round window membrane and into the inner ear of the subject to provide modulation of

glutamate-mediated neurotransmission without causing significant clinical hearing loss associated with suppression of AMPA receptor-mediated signals.

15. **(Currently Amended)** The method of claim 14, wherein the agent is ~~an NMDA receptor antagonist administered by diffusion across a middle-inner ear membrane.~~

16. **(Currently Amended)** The method of claim 15, wherein the ~~NMDA receptor antagonist is selected from the group consisting of: D-AP5, MK-801, 7-chlorokynurename, agent is gacyclidine, and derivatives or analogues thereof.~~

17. **(Currently Amended)** The method of claim ~~14~~15 wherein the agent is delivered to the round window membrane of the inner ear for a period of at least about 3 days.

18. **(Original)** The method of claim 14, wherein the agent is delivered at a rate of from about 0.1 mg per hour to 200 mg per hour, continually, for a period of at least 24 hours.

19. **(Previously Presented)** The method of claim 14, wherein the inner ear disorder comprises tinnitus.